Dosing Underway in Phase 2a Trial of PP405 for Androgenetic Alopecia

Dosing underway in phase 2a trial of PP405 for androgenetic alopecia

The first patients have been dosed in a phase 2a clinical trial of PP405 for the treatment of androgenetic alopecia, Pelage Pharmaceuticals announced in a press release. The randomized, placebo-controlled trial will evaluate the safety and efficacy of PP405 in 60 men and women with the condition, also known as pattern baldness.

Oxyresveratrol Enhances Hair Regeneration in Human Dermal Papilla Cell and Androgenetic Alopecia Mouse Model

Researchers evaluated the effects of oxyresveratrol on human follicle dermal papilla cells and an androgenetic alopecia mouse model. [Scientific Reports] Full Article